To compare the long-term outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of known prognostic factors after treatment with R-CVP.
INTRODUCTION
Although prognostic factors for patients with follicular lymphoma (FL) have been studied extensively, it has been unclear until recently which are the most useful in a clinical setting and whether these now apply after the widespread incorporation of rituximab (R) into first-line therapy.
The International Prognostic Index (IPI) for aggressive lymphomas 1 is predictive of outcome in FL, but its utility is limited because few patients (10% to 15%) fall into the high-risk group. A scoring system specifically designed for FL-the Follicular Lymphoma Prognostic Factor Index (FLIPI)-was developed through an international cooperative study. 2 This index divides patients into risk groups using five prognostic factors: age (Ͼ 60 v Յ 60 years), Ann Arbor stage (III to IV v I to II), hemoglobin (Ն 12 v Ͻ 12 g/dL), number of affected nodal areas (Ͼ four v Յ four), and serum lactate dehydrogenase (LDH) level (Ͼ normal v Յ normal). Three risk groups were identified containing approximately equal numbers of patients: low risk (zero to one adverse factors), intermediate risk (two adverse factors, hazard ratio [HR] ϭ 2.3), and poor risk (three to five adverse factors, HR ϭ 4.3). This index allows for comparison of results across trials and may allow for studies of different therapies in the various groups.
Until recently, standard treatment for advanced symptomatic FL was chemotherapy. Alkylating agents, anthracyclines, and purine analog-based regimens have all been used, with no regimen conclusively demonstrating a superior outcome with the possible exception of anthracycline/interferon-␣ combinations. 3 More recently, improvements in long-term outcome in patients with FL, including prolongation of overall survival (OS), have been demonstrated in large randomized studies by the addition of R to standard chemotherapy combinations in the first-line treatment of FL. [4] [5] [6] [7] Because R with chemotherapy is now widely used for first-line treatment of FL, it is important to establish whether these same prognostic factors still apply now as they did in the pre-R era.
We report 53-month median follow-up data from a phase III study comparing eight cycles of R plus cyclophosphamide, vincristine, and prednisone chemotherapy (R-CVP) with eight cycles of CVP alone in patients with previously untreated FL. This analysis includes survival data as well as univariate and multivariate analyses of the prognostic factors for time to progression (TTP) in both arms of the study.
PATIENTS AND METHODS

Patients
As discussed in detail elsewhere, 4 patients were eligible for the study if they had previously untreated CD20 ϩ stage III or IV FL and required therapy in the opinion of the treating clinician.
This study complied with all the requirements of the Declaration of Helsinki and its current amendments and was conducted in accordance with Good Clinical Practice guidelines.
Treatment
Eligible patients were randomly assigned (1:1) to treatment with R-CVP or CVP alone for a maximum of eight cycles of therapy, as described previously. 4 Random assignment was performed centrally for all participating centers, using stratification according to center and IPI scores (0 or 1 v 2 or 3).
1
Assessments
Disease response was determined in accordance with standard criteria.
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The primary end point was time to treatment failure (TTF), defined as the time between random assignment and any of the following events: progressive disease, relapse after response, institution of new antilymphoma treatment, stable disease after cycle 4 (SD4), or death resulting from any cause. Secondary parameters included TTP, response rates, OS, duration of response, time to next antilymphoma treatment or death, and disease-free survival. In the TTP analysis, patients who had SD4 were not censored at this time point but were followed, in the same way as responders, until progressive disease or death occurred, regardless of second-line therapy.
Statistical Analyses
A sample size of 318 patients was calculated as sufficient to detect a 50% increase in the median TTF in patients treated with R-CVP compared with those treated with CVP alone, with 85% power at a two-tailed significance level of 5%.
All analyses of efficacy and safety were performed on an intention-totreat (ITT) basis. TTF and TTP were analyzed using the log-rank test, and the results were expressed as Kaplan-Meier plots.
TTP was subsequently analyzed using the Cox regression model to assess the effects of treatment according to various baseline prognostic factors. The following factors were considered: age, number of extranodal sites, bone marrow involvement, LDH levels, ␤ 2 -microglobulin levels, presence of B symptoms, bulky disease (defined as nodal or extranodal mass Ͼ 7 cm in its greater diameter), British National Lymphoma Investigation (BNLI) criteria for therapy, number of affected nodal areas, hemoglobin levels, composite IPI score, and composite FLIPI score.
Univariate analyses were performed first, including one factor in the model in addition to trial treatment group and center pool. Terms for the interaction of each prognostic factor with trial treatment were included in order to assess consistency of the treatment effect.
Multivariate analyses with both forward and backward selection of prognostic factors (␣ ϭ .05) were conducted to assess the predictive value of various parameters on TTP in the presence of the trial treatment effect. Owing to the composite nature of the IPI and FLIPI scores and because they share a number of features, multivariate analysis was carried out in three different ways. First, the FLIPI score was included as a composite along with the other prognostic factors that are not incorporated in the FLIPI. Second, the IPI score was included as a composite along with the other prognostic factors that are not incorporated in the IPI. Third, the individual components of each of the composite FLIPI and IPI indexes were included, together with other prognostic factors.
All P values are two-tailed. Statistical analyses were performed using SAS software (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
As previously reported, 4 the final analysis population consisted of 159 patients in the CVP group and 162 patients in the R-CVP group. More than 80% of the patients had at least one symptom requiring therapy according to local treatment guidelines (BNLI, Groupe d'Etudes de Lymphoma Folliculaire, Eastern Cooperative Oncology Group/Southwest Oncology Group).
There were no clinically relevant differences between the two groups by any demographic, clinical, or pathologic criteria (Table 1) . Although most patients had an IPI score of 0 to 2, 15% of patients receiving CVP and 13% receiving R-CVP had an IPI score of 3 to 4. According to the FLIPI, 45% of patients in the CVP group and 38% in the R-CVP group had scores of 3 to 5. All patients had an Ann Arbor disease stage of III or IV. Because patients had to have stage III/IV disease for enrollment, the FLIPI risk distribution in this cohort was skewed toward a higher proportion of high-risk patients when compared with an unselected population with FL.
Treatment
As previously reported, 4 68% of patients in the CVP arm and 85% of patients in the R-CVP arm completed the eight scheduled cycles of therapy; the difference is the result of fewer patients in the R-CVP arm withdrawing after cycle 4 after an insufficient response (Fig 1) .
Efficacy
The primary end point for this study, TTF, was significantly prolonged in patients receiving R-CVP compared with those who received CVP alone (P Ͻ .0001; Table 2 ). Statistically significant and clinically relevant improvements in all other time-to-event variablesincluding TTP (P Ͻ .0001), response duration (P Ͻ .0001), and time to next antilymphoma treatment or death (P Ͻ. 0001)-were demonstrated in patients treated with R-CVP compared with those who received CVP alone ( Table 2 ). The median duration of response in R-CVP patients achieving a complete remission (CR) or unconfirmed CR (CRu) has not yet been reached and is 25 months for patients achieving a partial remission (PR).
With a median 53 months of follow-up, a significant improvement in OS has now been demonstrated after treatment with R-CVP versus CVP alone (P ϭ .029; Table 2 ; Fig 2) .
An exploratory analysis performed to assess the outcome of patients in the CVP group based on the type of their first second-line treatment did not confirm a significant difference in OS between the groups of patients receiving treatment at first relapse with a R-containing regimen and those receiving treatment without R. (logrank P ϭ .1788).
Of the 45 patients treated with a R-containing regimen, 34 (76%) of 45 were still alive at the time of the analysis as compared with 56 (64%) of 88 patients treated with a regimen without R. Univariate and multivariate Cox regression analyses were ‡Stage III-2: involvement of lymph nodes on both sides of diaphragm. Abdominal disease including para-aortic, mesenteric, and iliac involvement with or without disease in the upper abdomen.
§Higher scores indicate a greater risk of death. B symptoms were defined as fever, weight loss, and night sweats. ¶Bulky disease is defined as nodal or extranodal mass Ͼ 7 cm at its greater diameter. #The percentage calculation was not based on the 159 and 162 patients in the CVP and R-CVP groups, respectively, because LDH normal values were unavailable for seven patients in the CVP group and 10 patients in the R-CVP group.
conducted to assess the efficacy of treatment in terms of TTP according to various baseline prognostic factors.
Univariate analyses. P values resulting from the analyses by patient subgroups are reported without stratification by center pools. Baseline FLIPI scores categorized patients as follows: low risk (zero to one risk factors), 17%; intermediate risk (two risk factors), 39%; and high risk (three to five risk factors), 44%. Baseline IPI categorized patients as follows: zero to one risk factors, 47%; two risk factors, 38%; and three to four risk factors, 15%.
Although FLIPI was conceived as a prognostic index for OS, there are too few deaths reported in this study at this time point to draw any conclusion using this parameter for subgroup analysis. Here, TTP is used as a possible surrogate for OS.
The addition of R to CVP was associated with significantly prolonged TTP compared with CVP alone in all FLIPI subgroups (Fig 3) , all IPI subgroups, and irrespective of baseline histology, presence or absence of B symptoms, and presence or absence of bulky disease (Table 3 ; Fig 4) .
Most patients (80%) had baseline hemoglobin of at least 12 g/dL. A significant improvement in TTP was observed in these patients after treatment with R-CVP versus CVP alone (P Ͻ .0001; Table 3 ; Fig 4) . However, no difference in TTP was observed between the treatment groups in the minority of patients (n ϭ 64) with baseline hemoglobin less than 12 g/dL (P ϭ .3941; Table 3 ; Fig 4) .
Multivariate analyses. Multivariate analysis was used to assess the prognostic value of various parameters (BNLI criteria, age, extranodal sites, LDH, FLIPI, IPI, bone marrow involvement, elevated ␤ 2 -microglobulin, B symptoms, bulky disease, nodal areas, hemoglobin level) on outcome in terms of TTP in the presence of the trial treatment effect. Only the FLIPI (categorized as 0 to 2 v 3 to 5 in the analysis) was found to be a significant prognostic parameter for TTP in addition to the trial treatment. Patients with a FLIPI score of 0 to 2 who received R-CVP had the longest TTP. No other prognostic factor improved the predictive power.
In two further multivariate analyses (one utilizing IPI instead of FLIPI, the other considering neither of the composite factors FLIPI and IPI), only hemoglobin level and number of nodal areas were found to be statistically significant predictors of TTP in addition to trial treatment.
Adverse Events
As previously reported, 4 the incidence of adverse events was similar in the R-CVP and CVP groups. Although there was a higher incidence of grade 3/4 neutropenia during treatment with R-CVP (24%) compared with CVP (14%), this did not translate into a higher rate of infections. There were no treatment-related deaths.
DISCUSSION
These follow-up data (median, 53 months) confirm that the addition of R to CVP chemotherapy in patients with previously untreated FL significantly improves the CR rate, TTF, TTP, duration of response, disease-free survival, and time to next antilymphoma treatment compared with CVP chemotherapy alone. These data with long-term follow-up are consistent with the early results reported from this trial. 4 An improvement in OS has also now been observed, although the delay between first relapse and death is long.
Thirty-four percent (45 of 133) of the patients receiving secondline therapy in the CVP group and 21% (18 of 84) of patients receiving second-line therapy in the R-CVP group were treated with R monotherapy or R-containing immunochemotherapy regimens, suggesting that, because there is an OS benefit in the R-CVP group, not all patients relapsing after chemotherapy alone can have successful salvage treatment with second-line R-containing therapy.
The study design allowed for collection of the second-line treatment only; therefore, the proportion of patients treated with R at subsequent relapses over the length of their disease is likely to be higher than the 34% reported here, especially as the indication for R treatment of patients with FL was extended to cover its use with chemotherapy after 2004. This is one of four randomized trials to show a significant improvement in progression-free survival (PFS) or TTP and OS associated with the addition of R to standard chemotherapy in first-line treatment of FL. Hiddemann et al 5 demonstrated a significant improvement in PFS and OS with the addition of R to cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy in patients with untreated, advanced-stage FL: After 3 years, only six of 223 patients in the R-CHOP arm had died compared with 17 of 205 patients treated with CHOP alone (P ϭ .016). Herold et al 6 demonstrated significant prolongation of OS with R, mitoxantrone, chlorambucil, and prednisolone arm compared with mitoxantrone, chlorambucil, and prednisolone alone in patients with previously untreated advanced FL (4-year OS in FL patients, 87% v 74%; P ϭ .0096). 6 Foussard et al 7 initially reported a significant improvement in OS in this setting by the addition of R to cyclophosphamide, doxorubicin, etoposide, prednisone, and interferon compared with cyclophosphamide, doxorubicin, etoposide, prednisone, and interferon alone (OS at 42 months, 91% v 84%; P ϭ .029), but recent 5-year follow-up suggests that this benefit is confined to those patients in the high FLIPI groups. In each of these four studies, the benefits achieved by the addition of R to chemotherapy were attained without substantially increasing toxicity. The OS rates for the other reported studies for chemotherapy alone and R-chemotherapy combinations (90% v 95% at 2 years; 5 74% v 87% at 4 years; 6 and 84% v 91% at 42 months, 7 respectively) may be superior to those reported here (77% v 83% at 48 months; Table 2 ), but it is important to note that patients in the other studies who received the more aggressive treatment regimens also received interferon-␣. The effect is similar in all studies that compare chemotherapy versus R plus chemotherapy. In our study, the additional benefit of R-CVP over chemotherapy alone is estimated to be a 40% reduction in the risk of death (HR ϭ 0.60; 95% CI, 0.38 to 0.96). There is as yet no study directly comparing anthracycline-and non-anthracyclinebased regimens and therefore no proof that such intensive regimens confer long-term benefit compared with R-CVP. It is also worth noting that patients achieving a CR with R-CVP have a prolonged disease-free survival, suggesting that such patients may not require more intensive treatment.
The Cochrane Group meta-analysis of seven randomized studies comparing R-chemotherapy with chemotherapy alone in a combined total of 1,943 patients with previously untreated and relapsed/refractory FL, mantle-cell lymphoma (MCL), or other indolent lymphoma, also recently confirmed a significant survival benefit associated with the addition of R to chemotherapy both for 
Fig 4.
Cox regression model of time to treatment progression among patients assigned to chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP) or with CVP plus rituximab, according to baseline prognostic factors. BNLI, British National Lymphoma Investigation; BM, bone marrow; LDH, lactate dehydrogenase; B 2 M, ␤ 2 -microglobulin; FLIP index, Follicular Lymphoma International Prognostic Index; IPI, International Prognostic Index; CRF, case record form.
